Paper Details

  1. Home
  2. Paper Details

Antihypertensive effects of moexipril, a new ACE inhibitor, as add-on therapy to nifedipine in patients with essential hypertension.

Author: FoxA, PerssonB, StimpelM, WidgrenB R

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Moexipril, an ACE inhibitor, was well tolerated and provided additional antihypertensive effects when added to nifedipine retard in patients with essential hypertension. All doses of moexipril (3.75 mg, 7.5 mg, and 15 mg) reduced diastolic blood pressure significantly compared to placebo.
Paper Details　
Original Abstract of the Article :
Moexipril is a new nonpeptide angiotensin-converting enzyme (ACE) inhibitor with an intermediate duration of action. The antihypertensive efficacy and safety of moexipril as add-on therapy to nifedipine retard (20 mg b.i.d) was compared to placebo during 8 weeks in a double-blind trial with a parall...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/00005344-199507000-00012

データ提供：米国国立医学図書館（NLM）

Moexipril: A New Oasis in the Desert of Antihypertensive Therapy

Moexipril is a new angiotensin-converting enzyme (ACE) inhibitor with an intermediate duration of action. This study evaluated the antihypertensive efficacy and safety of moexipril as add-on therapy to nifedipine in patients with essential hypertension.

The researchers conducted a double-blind, parallel group trial involving 203 patients with essential hypertension. Patients were randomly assigned to receive either placebo or moexipril (3.75 mg, 7.5 mg, or 15 mg) in addition to nifedipine. The study found that all doses of moexipril significantly reduced diastolic blood pressure (DBP) compared to placebo, with the highest dose (15 mg) demonstrating the most significant improvement. Moexipril was well tolerated, and the overall incidence of adverse experiences was lower than in the placebo group.

Moexipril: A Promising Antihypertensive Option

The study demonstrates the efficacy and safety of moexipril as add-on therapy to nifedipine in managing essential hypertension. The drug's effectiveness in lowering blood pressure and its favorable safety profile make it a valuable tool for physicians treating hypertension.

Navigating the Shifting Sands of Hypertension Management

For individuals with hypertension, this study highlights the importance of working closely with your doctor to find the most effective treatment strategies. There are various medications available, and a personalized approach is crucial for achieving optimal blood pressure control and minimizing side effects.

Dr. Camel's Conclusion

This study unveils a new oasis in the desert of antihypertensive therapy, showcasing the potential of moexipril to effectively manage high blood pressure. Its favorable safety profile and effectiveness make it a promising option for individuals with hypertension, allowing them to navigate the shifting sands of their condition with greater ease and control.

Date :
  1. Date Completed 1995-11-22
  2. Date Revised 2019-07-24
Further Info :

Pubmed ID

7564369

DOI: Digital Object Identifier

10.1097/00005344-199507000-00012

Related Literature

Article Analysis
・Effects of moexipril
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.